BRAF V600 Mutation, Tissue/Block

What is BRAF V600 mutation detection test?

BRAF is a gene involved in the MAPK signaling pathway, which controls cell growth. BRAF V600 mutation detection test is a molecular test performed on tumor tissue (FFPE blocks) to detect mutations in the BRAF gene, specifically the V600 mutation. The V600 mutation leads to constant activation of BRAF, promoting uncontrolled cancer cell growth.

Why consider BRAF V600 mutation detection test?

• To identify patients eligible for targeted therapies (e.g., BRAF inhibitors like vemurafenib, dabrafenib, or combination therapy).
• BRAF V600E is associated with poor prognosis in some cancers (e.g., colorectal cancer) and distinct biological behaviour of tumors.
• Guides personalized treatment decisions and clinical trial enrolment.

Who should get tested for BRAF V600 mutation detection test?

BRAF V600 mutation detection test can be recommended for patients with colorectal cancer (CRC), melanoma, thyroid cancer, non-small cell lung cancer (NSCLC) and other solid tumors where BRAF mutation–driven therapy is being considered. BRAF V600 mutation detection test is also advised especially for advanced/metastatic cases, patients being considered for targeted therapy or clinical trials and tumors with aggressive or unusual histology

More Information

OTHER NAMES: BRAF V600E Mutation Testing, Tumor BRAF Genetic Testing (FFPE Tissue), BRAF Molecular Analysis (Tissue Block), BRAF Mutation Assay – V600 Codon, Solid Tumor BRAF Testing

The BRAF gene produces a protein that helps control cell growth through the MAPK signaling pathway.
A mutation at position V600 (usually called V600E) changes the BRAF protein, making it constantly active. This leads to uncontrolled cell division and contributes to cancer development. It is a driver mutation found in several cancers such as melanoma (skin cancer), colorectal cancer, thyroid cancer, non-small cell lung cancer (NSCLC) and others.